Navigation Links
Isis Pharmaceuticals to Present at the 2013 Deutsche Bank BioFEST
Date:11/25/2013

CARLSBAD, Calif., Nov. 25, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 8:25 a.m. ET in Boston, MA.

(Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and sho
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "12th Annual Report ... report to their offering. The ... Manufacturing Capacity and Production is the most recent ... current and projected future capacity and production. The ...
(Date:8/28/2015)... 2015 Research and ... the "Investigation Report on China,s Insulin Aspart ... Developed by Novo Nordisk, insulin aspart (under ... drug for the treatment of diabetes. Compared with ... insulin analog, starts working fast and reports higher ...
(Date:8/28/2015)... 28, 2015 Perrigo Company plc ("Perrigo") (NYSE: ... N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote regarding ... "Our views of Mylan,s offer to Perrigo shareholders have ... our Board,s careful reflection of the value available to ... choices that Mylan has allowed its shareholders to consider," ...
Breaking Medicine Technology:12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... SYDNEY, Australia, Aug. 17 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Phase 3,clinical trial of Bronchitol for the treatment ... efficacy data from the trial is expected to ... trial commenced its dosing phase in,April 2007, reached ...
... Activity, VOORHEES, N.J., Aug. 14 ... and mortality in recipients of hematopoietic,stem cell ... are,serious and range from gastrointestinal disease to ... order to prevent CMV infection and reduce ...
Cached Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is a ... field in the military. All too often VA hospitals treat patients with harmful and ... the VA program over a decade ago, the reality is that only 10% of ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted ... it will be devoting an entire short segment to the subject of diabetes. Diabetes ... globe on a daily basis, but recent advancements in medical science may prove to ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... School of Medicine (BUSM) have shown that patients ... of their degree of adherence to antihypertensive medications. ... Hypertension could have an immediate impact ... held assumption. The BUSM researchers studied ...
... for PCV-7 vaccine supported by study findings , TUESDAY, ... will be relieved by new findings that show a ... against pneumonia and other infections. , The current recommended ... of three primary doses before the age of 6 ...
... women more likely to die, but questions remain , TUESDAY, ... cancer outcomes, with black women more likely to die from ... new research shows. , , For a quarter of a ... in certain cancers. The racial disparity "first emerged about 25 ...
... Texas, July 7 Perot Systems (NYSE: PER ... case studies highlighting the success of several of its healthcare ... process solutions. The videos feature the Perot Systems clients ... Pilgrim Health Care , and Northern Arizona Healthcare . ...
... ... a New Century (The Collaboration) announced today the availability of a ... savingsdrugcard.com provides a free drug card that will help all Arizonans ... card by visiting http://www.SavingsDrugCard.com and can immediately start saving ...
... suggests proton pump inhibitors could aggravate acid trouble , TUESDAY, ... heartburn and acid reflux may actually cause heartburn. , A ... found that treatment with a proton pump inhibitor (PPI) actually ... took the medication for eight weeks. , Although the ...
Cached Medicine News:Health News:Intensive management can improve blood pressure in non-adherent hypertensive patients 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2Health News:New Clues to Race Gap in Breast Cancer Outcomes 2Health News:New Clues to Race Gap in Breast Cancer Outcomes 3Health News:Video: Perot Systems Unveils Series of Healthcare Video Case Studies 2Health News:Popular Prescription Drug Discount Card Now Available in Arizona Online 2Health News:Popular Prescription Drug Discount Card Now Available in Arizona Online 3Health News:Heartburn Drugs May Contribute to the Problem 2Health News:Heartburn Drugs May Contribute to the Problem 3
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
... Oil is a clear, colorless oil ... of the UV-VIS spectrum. Resolve is ... viscosity, is non-drying and non-hardening, and ... Resolve contains no PCBs, eliminating toxicity ...
Medicine Products: